Alzamend Neuro, Inc. Banner Image

Alzamend Neuro, Inc.

  • Ticker ALZN
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Alzamend Neuro, Inc. Logo Image
  • 1-10 Employees
  • Based in Atlanta, Georgia
Alzamend is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BPD, MDD and PTSD. Their mission is to rapidly develop and market safe and effective treatments. Their current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combinationMore of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of their product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.
Alzamend Neuro, Inc.

Most Recent Annual Report

Alzamend Neuro, Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

Alzamend Neuro, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!